CD8A and neoplasm: Using human pDCs and cDC2s differentiated from CD34+ hematopoietic stem cells, it has been reported that BDCA1+ cDC2s are superior in generating antigen-specific CD8 T cell immunity, although pDCs are superior in activating natural killer (NK)cells [65], suggesting that vaccines that combine both cDC2s and pDCs might achieve better anti-tumor efficacy.